title: Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
abstract: OBJECTIVE
  To rationally evaluate the effect of S-1 vs capecitabine for the treatment of gastric cancer.
  
  
  METHODS
  MEDLINE, EMBASE, Cochrane Controlled Trials Register, Google Scholar, and China Journal Full Text Database were accessed to collect clinical randomized controlled trials regarding the effect of S-1 vs capecitabine for the treatment of gastric cancer patients. Statistical analysis was performed by meta-analysis. Four randomized controlled trials met the inclusion criteria.
  
  
  RESULTS
  Compared with capecitabine regimens, the 1-year survival rate in gastric cancer patients was 0.80 (95%CI: 0.52-1.21, P = 0.29). The overall response rate of S-1 vs capecitabine was 0.94 (95%CI: 0.59-1.51, P = 0.93). Compared with capecitabine regimens, the most frequent hematologic toxicities were neutropenia (OR = 0.99, 95%CI: 0.65-1.49, P = 0.94) and thrombocytopenia (OR = 0.72, 95%CI: 0.31-1.67, P = 0.44). The most frequent non-hematologic toxicities included nausea (OR = 0.85, 95%CI: 0.56-1.28, P = 0.43) and hand-foot syndrome (OR = 0.16, 95%CI: 0.10-0.27, P < 0.00001).
  
  
  CONCLUSIONS
  The existing studies suggest that S-1 is not more effective than capecitabine in the treatment of gastric cancer patients, but does exhibit less toxicity with regard to hand-foot syndrome.
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: An-Bing
authors.initials: AB
authors.lastname: He
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Xiu-Lan
authors.initials: XL
authors.lastname: Peng
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Ji-Xing
authors.initials: JX
authors.lastname: Zhang
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Wei-Guo
authors.initials: WG
authors.lastname: Dong
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Ren-Feng
authors.initials: RF
authors.lastname: Luo
authors.affiliation: An-Bing He, Xiu-Lan Peng, Yan Tang, Department of Oncology, the Fifth Hospital of Wuhan, Wuhan 430050, Hubei Province, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Tang
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D004338:Drug Combinations; D060831:Hand-Foot Syndrome / Q000209:etiology; D006801:Humans; D016017:Odds Ratio; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000069287:Capecitabine
keywords: Capecitabine; Gastric cancer; Meta-analysis; Randomized controlled trials; S-1